J&J Closes $885M Alzheimer's Drug Deal With Elan
Johnson & Johnson has completed an $885 million deal to own a stake in Elan Corp. and gain rights to the Irish biotechnology company's Alzheimer's disease treatment program, now that Elan...To view the full article, register now.
Already a subscriber? Click here to view full article